Nephrology experts discuss how CKD care has evolved in 2026, including SGLT2 inhibitors, finerenone, GLP-1 receptor agonists, and personalized treatment.
Matthew Breeggemann, MD
Advertisement
Matthew C. Breeggemann, MD is a nephrologist who cares for patients with kidney disease. He is medical director of UCSF's Kidney Stone Prevention Clinic, where he treats patients with a variety of kidney stone disorders in collaboration with the department of urology.
Articles by Matthew Breeggemann, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
GLP-1 Receptor Agonists Reshape CKD Treatment Sequencing, With Pranav Garimella, MD
2
Omalizumab Outperforms Oral Immunotherapy for Multifood Allergy
3
Long-Term Tegoprubart Data in Kidney Transplantation, With Andrew Adams
4
Allergists Debate Newer Nonsteroidal Topicals for Atopic Dermatitis
5